Suppr超能文献

特发性甲状旁腺功能亢进症中锝 99m 甲氧基异丁基异腈 SPECT 强度评分系统。

Sestamibi SPECT intensity scoring system in sporadic primary hyperparathyroidism.

机构信息

Division of Endocrine Surgery, Department of Surgery, University of Pittsburgh School of Medicine, Kaufmann Building, Suite 101, 3471 Fifth Avenue, Pittsburgh, PA 15213, USA.

出版信息

World J Surg. 2009 Mar;33(3):426-33. doi: 10.1007/s00268-008-9841-0.

Abstract

BACKGROUND

Most cases of sporadic primary hyperparathyroidism (PHP) are due to a single parathyroid adenoma and can be treated with minimally invasive parathyroid exploration guided by sestamibi SPECT imaging and intraoperative parathyroid hormone monitoring. Successful surgery depends on identification of the 10-15% of patients with multiglandular disease. Failed initial parathyroid exploration is both costly and morbid. We examined whether a sestamibi SPECT scoring system could predict anatomic findings in patients with PHP.

METHODS

Prospective data from 1,061 consecutive patients undergoing initial parathyroid exploration for PHP from March 6, 2000 to September 28, 2007 were reviewed. One nuclear medicine physician performed independent blinded review of 577 available dual time-point sestamibi SPECT scans, and scored the results into 1 of 5 categories: 0-negative, 1-possible, 2-probable, 3-definite adenoma, or 4-multiglandular disease. Intraoperative findings and outcomes at >5 months follow-up were examined. Chi-square and nonparametric analyses were used to evaluate variables for correlation.

RESULTS

Among patients with sestamibi SPECT scan results classified as either 0--negative or 1--possible adenoma, only 211/262 (81%) had a single adenoma, compared to 263/288 (91%) patients with scan results classified as 2--probable or 3--definite adenoma (p < 0.001). Positive predictive values increased in stepwise correlation with sestamibi SPECT image intensity: 1--possible 78.5%, 2--probable 94.3%, and 3--definite adenoma 98.8%. Multiglandular disease was present in 31/144 (22%) patients with a 0--negative scan versus 13/166 (8%) patients with a 3--definite adenoma scan (p = 0.0005). Only 7/27 (26%) patients with scans classified as 4-multiglandular had actual multiglandular disease. Negative scan results were associated with a greater risk of operative failure (p < 0.001).

CONCLUSIONS

A simple scoring system based on sestamibi SPECT intensity can predict the likelihood of single adenoma in PHP. Even the best localizing study cannot exclude multiglandular disease preoperatively. Negative sestamibi SPECT scans are associated with a higher rate of operative failure. Because sestamibi SPECT scans of any category do not reliably identify multiglandular disease, expert surgeons must use validated adjuncts to avoid operative failure.

摘要

背景

大多数散发性原发性甲状旁腺功能亢进症(PHP)是由单个甲状旁腺腺瘤引起的,可以通过 SPECT 甲状旁腺显影引导的微创甲状旁腺探查术和术中甲状旁腺激素监测进行治疗。成功的手术取决于识别出 10-15%的多腺体疾病患者。初次甲状旁腺探查术失败既昂贵又有风险。我们研究了 SPECT 评分系统是否可以预测 PHP 患者的解剖学发现。

方法

对 2000 年 3 月 6 日至 2007 年 9 月 28 日期间因 PHP 进行初次甲状旁腺探查的 1061 例连续患者的前瞻性数据进行了回顾性分析。一名核医学医师对 577 份可用的双时相 SPECT 扫描进行了独立的盲法评估,并将结果分为 5 个类别之一:0-阴性、1-可能、2-可能、3-明确的腺瘤或 4-多腺体疾病。检查了术后 5 个月以上的术中发现和结果。使用卡方和非参数分析评估变量相关性。

结果

在 SPECT 扫描结果分类为 0-阴性或 1-可能的腺瘤的患者中,只有 262/262(81%)的患者为单个腺瘤,而扫描结果分类为 2-可能或 3-明确的腺瘤的患者中,有 288/288(91%)(p<0.001)。SPECT 图像强度的逐步相关性增加了阳性预测值:1-可能为 78.5%,2-可能为 94.3%,3-明确为腺瘤为 98.8%。在 0-阴性扫描的 144 例患者中,有 31/144(22%)存在多腺体疾病,而在 3-明确为腺瘤的扫描的 166 例患者中,有 13/166(8%)存在多腺体疾病(p=0.0005)。只有 27/27(26%)的扫描分类为 4-多腺体的患者实际上存在多腺体疾病。阴性扫描结果与手术失败的风险增加相关(p<0.001)。

结论

基于 SPECT 强度的简单评分系统可以预测 PHP 中单个腺瘤的可能性。即使是最好的定位研究也不能在术前排除多腺体疾病。阴性 SPECT 扫描与更高的手术失败率相关。由于任何类别的 SPECT 扫描都不能可靠地识别多腺体疾病,因此经验丰富的外科医生必须使用经过验证的辅助手段来避免手术失败。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验